Analysis of the Classification of Herpes Zoster Virus and Principles for Improving Laboratory Diagnostics

A serious health concern that can impact people of any age is herpes zoster. People over 50, those with impaired immune systems, and those using immunosuppressive medications are more likely to experience it. The varicella zoster virus reactivation is the cause. This reactivation is influenced by cell-mediated immunity. Before a rash appears, frequent symptoms include fever, discomfort, and itching. The most frequent side effect of herpes zoster is post-herpetic neuralgia. Age, immunological state, and the timing of therapy initiation all affect risk factors and problems related to herpes zoster. Herpesvirus-induced infections of the central nervous system (CNS) have different epidemiologies depending on host characteristics and geographic distribution. Early diagnosis and treatment can save lives. This study assessed an internal laboratory methodology for cerebrospinal fluid (CSF) molecular testing criteria, examined the epidemiology of herpesvirus CNS infections in Western Greece, and compared clinical and laboratory results with global data. 940 out of 4300 CSF samples were eligible for RT-PCR detection of varicella zoster virus (VZV) and herpes simplex virus (HSV-1, HSV-2) during the research period. 53 (5.63%) of them tested positive: 7 HSV-2, 9 HSV-1, and 37 VZV. The greatest CSF white blood cell (WBC) counts (231/mm3) were seen in HSV-2 cases, which were found in younger patients (median age 41), followed by VZV (125/mm3) and HSV-1 (26/mm3). HSV-2 infections had greater levels of CSF protein. The most sensitive imaging technique for identifying CNS inflammation was magnetic resonance imaging (MRI). These findings show that VZV is the most common herpesvirus in this area, highlighting the importance of prompt molecular identification and high clinical suspicion in elderly patients.